Business Basics
Assignment II: Business Basics
Biogen Idec
Biogen Idec is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis and other autoimmune disorders, neurodegenerative diseases and haemophilia. Biogen Idec was formed in 2003 from the merger of two companies, Biogen Inc., founded in 1978, and IDEC Pharmaceuticals Corporation, founded in 1985. It is one of the largest biotechnology companies in the world. Biogen Idec covers the entire value chain, from R&D to worldwide sales.
Biogen Idec displayed strong operational, commercial and financial performance in 2006. However, new market opportunities and the challenges of the next decade have led the company’s management to adopt a new strategy called ‘2015 Vision’. Biogen Idec is the oldest independent biotechnology company in the world. Patients worldwide benefit every day from its industry leading multiple sclerosis (MS) product. Biogen derives most of its sale from MS drugs.
Biogen Idec's success depends on several factors, including its research and development (R & D) product pipeline, patent expirations, and partnership agreements. Like many pharmaceutical companies, however, the company will likely succeed or fail on the back of a few key blockbuster drugs. The company's products must compete against products from a wide variety of companies, ranging from pharmaceutical giants like GlaxoSmithKline that have enormous R&D budgets to similarly sized biotech firms with the same areas of expertise. For a biotech company, Biogen Idec has a large R&D budget, a young product pipeline, and limited product diversity.
The reason behind the success thus far-
Revenue gains were led by the performance of their marketed therapies:
AVONEX® revenues increased 2% year-over-year to $774 million.
TYSABRI® (natalizumab) revenues for the Company increased 38% year-over-year to $387 million primarily due to the acquisition of Elan’s rights in
Biogen Idec
Biogen Idec is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis and other autoimmune disorders, neurodegenerative diseases and haemophilia. Biogen Idec was formed in 2003 from the merger of two companies, Biogen Inc., founded in 1978, and IDEC Pharmaceuticals Corporation, founded in 1985. It is one of the largest biotechnology companies in the world. Biogen Idec covers the entire value chain, from R&D to worldwide sales.
Biogen Idec displayed strong operational, commercial and financial performance in 2006. However, new market opportunities and the challenges of the next decade have led the company’s management to adopt a new strategy called ‘2015 Vision’. Biogen Idec is the oldest independent biotechnology company in the world. Patients worldwide benefit every day from its industry leading multiple sclerosis (MS) product. Biogen derives most of its sale from MS drugs.
Biogen Idec's success depends on several factors, including its research and development (R & D) product pipeline, patent expirations, and partnership agreements. Like many pharmaceutical companies, however, the company will likely succeed or fail on the back of a few key blockbuster drugs. The company's products must compete against products from a wide variety of companies, ranging from pharmaceutical giants like GlaxoSmithKline that have enormous R&D budgets to similarly sized biotech firms with the same areas of expertise. For a biotech company, Biogen Idec has a large R&D budget, a young product pipeline, and limited product diversity.
The reason behind the success thus far-
Revenue gains were led by the performance of their marketed therapies:
AVONEX® revenues increased 2% year-over-year to $774 million.
TYSABRI® (natalizumab) revenues for the Company increased 38% year-over-year to $387 million primarily due to the acquisition of Elan’s rights in